替米沙坦联合硝苯地平控释片治疗对冠心病伴轻中度高血压患者炎性因子、血管内皮功能及左心室功能的影响  

Effects of telmisartan combined with nifedipine controlled release tablet on inflammatory factors,vascular endothelial function and left ventricular function in patients with coronary heart disease with mild to moderate hypertension

作　　者：郭峰 张宝娓[2] 朱正炎 GUO Feng;ZHANG Bao-wei;ZHU Zhcng- yan(Dpartmet of Cardicdogy,Shunyi Hospitcd,Beijing 101300,China;Dpartmnt of Cardicdogy,No .1 Hospitcd of Peking University,Beijing 100034,China)

机构地区：[1]北京市顺义区医院心内科,北京101300 [2]北京大学第一医院心内科,北京100034

出　　处：《海南医学院学报》2017年第20期2757-2760,共4页Journal of Hainan Medical University

基　　金：北京市卫生局资助基金(201712344)~~

摘　　要：目的:探讨替米沙坦联合硝苯地平控释片治疗对冠心病伴轻中度高血压患者炎性因子血管内皮功能及左心室功能的影响。方法:92例冠心病伴轻中度高血压患者随机分为对照组(n=46)和观察组(n=46),对照组给予硝苯地平控释片治疗,在对照组治疗基础上,观察组给予替米沙坦治疗,两组均治疗6个月。比较治疗前后两组血压、炎性因子、血管内皮功能及左心室功能水平。结果:两组治疗前SBP、DBP、hs-CRP、TNF-α、NO、ET-1、LVEF、LVEDD及LVESD水平比较,差异无统计学意义(P>0.05);治疗后,两组SBP、DBP、hs-CRP、TNF-α、ET-1、LVEDD及LVESD水平均显著低于组内治疗前(P<0.05),其中观察组治疗后SBP、DBP、hs-CRP、TNF-α、ET-1、LVESD水平较治疗后对照组水平显著降低,差异对比有显著性(P<0.05),两组治疗后LVEDD水平比较,差异无统计学意义(P>0.05);与组内治疗前水平相比,两组治疗后NO、LVEF水平均显著升高(P<0.05),且观察组显著高于对照组,差异有统计学意义(P<0.05)。结论:替米沙坦联合硝苯地平控释片治疗冠心病伴轻中度高血压,可有效控制血压,减轻机体炎性应激,改善患者血管内皮功能及左心室功能,具有重要临床价值。Objective：To investigate the effect of telmisartan combined with Nifedipine Controlled Release Tablet on inflammatory factors,vascular endothelial function and left ventricular function in patients with coronary heart disease with mild to moderate hypertension.Methods：A total of 92 cases of patients with coronary heart disease with mild to moderate hypertension were selected as the object of observation,according to the random data table,they were divided into the control group（n=46）and observation group（n=46）,and patients in the control group were treated with Nifedipine Controlled Release Table therapy,on this basis,the observation group patients were given telmisartan treatment,two groups were treated for 6 months.The levels of the blood pressure,inflammatory factors,vascular endothelial function and left ventricular function were compared between the two groups before and after treatment.Results：There were no significant differences in the levels of SBP,DBP,hs-CRP,TNF-α,NO,ET-1,LVEF,LVEDD and LVESD in the two groups before treatment（P〈0.05）;After treatment,two groups of SBP,DBP,hs-CRP,TNF-α,ET-1,LVEDD and LVESD levels were significantly lower than those in the same group before treatment（P〈0.05）,and after treatment,the levels of SBP,DBP,hs-CRP,TNF-α,ET-1 and LVESD in the observation group were significantly lower than those in the control group（P〈0.05）,while there were no significant difference in the level of LVEDD between the two groups after treatment（P〉0.05）;Compared with level in the group before treatment,the levels of NO and LVEF in the two groups were significantly increased（P〈0.05）,and the observation group[（82.13±19.01）μmol/L,（52.83±7.45）%]was significantly higher than the control group[（67.37±13.08）μmol/L,（49.47±6.96）%]（P〈0.05）.Conclusion：Telmisartan combined with Nifedipine Controlled Release Table in treating coronary heart disease with mild to moderate hypertension,can effectively control blood pressure,reduce the infla

关 键 词：冠心病伴轻中度高血压 替米沙坦 硝苯地平控释片 炎性因子 血管内皮功能 左心室功能 

分 类 号：R541.4[医药卫生—心血管疾病]